Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin

Study Overview
=================
Brief Summary
-----------------
Diabetes mellitus is associated with an increased risk of cardiovascular disease. Substantial clinical and experimental evidence suggest that both diabetes and insulin resistance cause a combination of endothelial dysfunctions, which may diminish the anti-atherogenic role of the vascular endothelium. Therefore, in patients with diabetes or insulin resistance, endothelial dysfunction may be a critical early target for preventing atherosclerosis and cardiovascular disease. It has been implicated as an independent risk factor for cardiovascular disease and premature cardiovascular mortality for patients with type 1 and type 2 diabetes mellitus, as well as for patients with essential hypertension. A complete biochemical understanding of the mechanisms by which hyperglycemia causes vascular functional and structural changes associated with the diabetic milieu still eludes us. In recent years, the numerous biochemical and metabolic pathways postulated to have a causal role in the pathogenesis of diabetic vascular disease have been distilled into several unifying hypotheses. The role of chronic hyperglycemia in the development of diabetic microvascular complications and in neuropathy has been clearly established. However, the biochemical or cellular links between elevated blood glucose levels, and the vascular lesions remain incompletely understood. A number of trials have demonstrated that statins therapy as well as angiotensin converting enzyme inhibitors is associated with improvements in endothelial function in diabetes. Although antioxidants provide short-term improvement of endothelial function in humans, all studies of the effectiveness of preventive antioxidant therapy have been disappointing. Actually, control of hyperglycemia thus remains the best way to improve endothelial function and to prevent atherosclerosis and other cardiovascular complications of diabetes.

Official Title
-----------------
Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin

Conditions
-----------------
Diabetes Mellitus Type 2 Platelets Reactivity Statin

Intervention / Treatment
-----------------
* Drug: Atorvastatin 80mg
* Drug: ALLOPURINOL 300 MG
* Drug: Atorvastatin 80mg AND allopurinol 300 mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diabetic patient; therapy with aspirin and insulin; patient well responders Exclusion Criteria: not diabetic patient; patients in dual antiplatelet therapy; patient with severe renal failure; patient poor responders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: statin only<br>30 DAYS OF STATIN THERAPY ATORVASTATIN 80 MG) | Drug: Atorvastatin 80mg<br>* 30 DAYS OF atorvastatin 80 mg<br>|
| Experimental: allopurinol only<br>30 DAYS OF ALLOPURINOL (300 MG) | Drug: ALLOPURINOL 300 MG<br>* 30 DAYS OF ALLOPURINOL 300 MG<br>|
| Experimental: statin and allopurinol<br>30 DAYS OF CO-ADMINISTRATION OF ATORVASTATIN AND ALLOPURINOL | Drug: Atorvastatin 80mg AND allopurinol 300 mg<br>* 30 days of atorvastatin and allopurinol 300 mg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of platelet reaction units Absolute changes in platelet reactivity (expressed as P2Y(12) reaction units by the point-of-care VerifyNow assay [Accumetrics, San Diego, California] After 30 days of treatment with each drug | Absolute changes in platelet reactivity (expressed as P2Y(12) reaction units by the point-of-care VerifyNow assay [Accumetrics, San Diego, California] | fter 30 days of treatment with each drug |